Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Newsfilter
Record Financial Performance: Cannara Biotech Inc. reported a 35% increase in net revenues to $26.6 million for Q2 2025, alongside a 52% rise in gross profit and a record Adjusted EBITDA of $7.1 million, marking the sixteenth consecutive quarter of positive results.
Market Expansion and Growth Strategy: The company expanded its national market share to 3.9%, with significant gains in Québec, Ontario, and Alberta, while activating two new grow zones to enhance production capacity and support ongoing product innovation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
